OmniAb, Inc.
- OABI
- NASDAQ
- Biotechnology
- Antibody Discovery Platform
- Therapeutic Antibodies
$4.69
Today +2.18%Quote Oct 19, 2026, 08:00 PM UTC
+4.92%over the last month
Max drawdown −12.8%From 1-month high −6.0%3 months +124.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About OmniAb
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments.
Where the money comes from
Q4 2025 revenue $8.4M
- Service$2.2M26.2%
- Royalty$218,0002.6%
- Other / not reported$6.0M71.2%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
89
Founded
2012
Market value
$681.9M
Quote Oct 19
Analyst target
$4.00
−14.7% from here
Floor
$4.65
0.9% below price
Resistance
$4.79
2.1% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about OABIPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free